At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 32 enrolled
Drug / intervention
LCZ696drug
Likely dose
LCZ696 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Open Label Study for Evaluation of the Safety, Tolerability and Efficacy of 8-week Treatment With LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction
In Brief
A Phase 3 clinical trial evaluating LCZ696 for Hypertension With Renal Dysfunction. Completed, enrolled 32 participants across 13 sites.
Detailed Summary
This study assessed the safety, tolerability, and efficacy of LCZ696 in hypertensive patients with renal dysfunction.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension With Renal Dysfunction
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2012
First PostedMay 2012
Primary CompletionMar 2013
TodayJul 2026
First PostedMay 8, 2012
Enrollment StartMay 1, 2012
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 14.2 years ago
Interventions
LCZ696drug
100 mg, 200 mg, 400 mg tablets.